Identifiers:  [STUDY_ID_REMOVED]   
Unique Protocol ID: 19-04020263 
Brief Title: PRAGMA (Prostate Radio Ablation Guided by 
[CONTACT_406567]) in 
Metastatic Prostate Cancer  
 
Version 5.0  
 
Version date: 26JUL2023 
 
IRB approval: 01AUG2023 
  
Document History 
  
Document Name  [CONTACT_406582] 4  5.0 26JUL2023  
Amendment 3  4.0 03FEB2022  
Amendment 2  3.0 05OCT2021  
Amendment 1  2.0 24JAN2020  
Initial Protocol  1.0 23JUL2019  
 
    
1 
 TITLE:  PRAGMA ( Prostate Radio Ablation Guided by [CONTACT_406568]) in metastatic  prostate cancer  
 
 
IRB Protocol #:   19-04020263    
Version 5.0 
Version Date :  26JUL2023  
 
 
Prin cipal Investigator :   Silvia Formenti, M.D.  
     
   
   
   
   
   
Co-Principal Investigator :    
   
 
  [INVESTIGATOR_406559] N. Sternberg, M.D.  
     
    
   
   
 
 
 
 
Statistician:   Karla Ballman, PhD  
     
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol [ADDRESS_512631] 
information.  Admin 
amendment approved on 
16NOV2021.  
No changes to the Informed consent  
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
7 
  
 
Summary of changes for version 3.0 dated 05OCT2021  
 
 
 
 
Summary of changes for version 2.0 dated 24JAN2020.  
 
1. Inclusion Criteria:  Must have metastatic prostate cancer proven on biopsy or imaging  
2. Exclusion Criteria: Removing criteria # 4 - Evidence of disease progression on bone 
scan, MR and/or CT  
3. Revised accrual ceiling to [ADDRESS_512632] . 
5. Updating QOL – AUA to I -PSS 
6. Study Calendar – clarifying that blood/stool collection is optional at all time points as 
stated in the informed consent.  
 
Informed consent changes:  
 
1. The protocol version date is incorrect - changing the footer of the informed consent.  
2. Making study ca lendar consistent with  the protocol.  
 Sections  Change  Rationale  
Principal Investigator 
[INVESTIGATOR_406560]. Josephine Kang to [CONTACT_406583] investigator 
[INVESTIGATOR_406561]. Josephine Kang to [CONTACT_406584] changes  Removed Maria Fenton -Kerimian as 
Nurse practitioner and Viji Nagaraj 
as study coordinator, Added Jessica 
Richman. Updated contact [CONTACT_406569] r 
personnel.  Change of personnel and 
contact [CONTACT_3031].  
Informed consent changes  
Principal Investigator 
[INVESTIGATOR_406562]. Josephine Kang to [CONTACT_406585] incipal investigator 
from [CONTACT_406586] to [CONTACT_406587] 19 -04020263  
Version  5.0 2 6JUL2023  
8 
  
Document History  
 
 
Document Name  [CONTACT_406582] 4  5.0 26JUL2023  
Amendment 3  4.0 03FEB2022  
Amendment 2  3.0 05OCT2021  
Amendment 1  2.0 24JAN2020  
Initial Protocol  1.0 23JUL2019  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
9 
  
 
Protocol Summar y  
 
PRAGMA ( Prostate Radio Ablation Guided by [CONTACT_406570]) in metastatic  prostate cancer   
 
IRB Protocol #:   19-04020263  
 
Short Title:     MRI -guided  prostate SBRT for metastatic prostate cancer  
Principal Investigator:   [INVESTIGATOR_124]. Ariel Marciscano  
Sample Size:   N = 20 
Accrual Ceiling:   This study  plans to enroll a total of 25 patients   
Study Population:   Patients with  metastatic prostate cancer  
Accrual Period:   2 years   
Study Design:   Single -arm study for safety  
 
Study Intervention Descri ption:   
MR-guided Prostate SBRT :  
Prostate SBRT has become  a standard of care for  the treatment of localized  prostate cancer . 
Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). 
Doses ranging from [ADDRESS_512633] demonstrated good outcomes with acceptable 
toxicity  when planning is delivered appropriately . 
There is emerging evidence that patients with non-localized prostate cancer also derive benefit 
from radiation (RT) to the primary tumor. The STAM PEDE multiarm British trial recently 
reported that patients with  low burden  metastatic prostate cancer have  an overall survival benefit 
from prostate RT. Doses of radiation used in the STAMPEDE trial were either [ADDRESS_512634]  (when indicated)  to visi ble nodules.  
In this study, we hope to demonstrate the safety of using 36.[ADDRESS_512635] (when indicated), in p atients with metastatic prostate  cancer.  
 
Hypothesis:   Patients with metastatic prostate cancer can undergo MRI -guided prostate SBRT  
witho ut significant adverse events , similar to what has been reported for patients with localized 
prostate cancer . 
 
We hypo thesize that prostate SBRT will be well -tolerated in metastatic prostate cancer patients, 
with quali ty of life outcomes similar to what has been reported in non -metastatic prostate cancer 
patients . 
 
We also hypothesize that prostate SBRT will impact lympho cyte counts and neutrophil 
Protocol [ADDRESS_512636] -RT and follow up datapoints.  
 
Primary objective: To assess safety of  deliver ing MRI -guide d prostate SBRT  in patients 
with metastatic  prostate cancer .  
 
   Treatment will be deemed safe of there is is no more than 3 acute >G3 likely radiation treatment 
related GI/GU toxicity within 3-6 months  after treatment (CTCAE 5.0 criteria)  completion .  
Given that the treatment plans will meet rigorous normal tissue constraints us ed for standard 
prostate SBRT that have been established now with up to 10 year follow up data in patients with 
localized prostate cancer,  we do not anticipate any inc reased toxici ty on this study  for metastatic 
prostat e cancer patients .  
 
  
Secondary objective : To obtain quality of life  and toxicity  data after prostate SBRT.  
We will measure  quality of life (HRQOL)  using : 1) the Expanded Prostate Cancer Index 
Composite (EPIC -26) short form questionnaire, 2) International Prostate Symptom Score (I -
PSS) . QOL assessments will occur  at baseline, 3 -6 months, and at 9 -12 months.  
Toxicity data will be measured with CTCAE 5.0  at 3-6 months, and at 9 -12 months.  
 
Correlative study o bjectiv es:  
1. To explore gut microbiome changes associated with prostate radiation  
2. To collect complete blood count (CBC) measurements at baseline, post -treatment and 3-[ADDRESS_512637] of SBRT on immune correlates and neutrophil lymphocyte 
ratios . 
 
 
 
 
 
 
 
 
  
  
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
11 
  
 SCHEMA  
 
  
 
 
 
 
 
 
 
  
 
  Patients with Metastatic Prostate Cancer  
 
 
 
Prostate SBRT (36.25 Gy in 5 fx)  
+/- optional SIB to [ADDRESS_512638] -RT CBC, microbiome to 
be collected  
  
 
 
 
 
  
 
Follow up visit at 3 -6 months, and 1 year:  
Assess GI/GU toxicity, EPIC -26, I-PSS  scores  
Collect CBC, microbiome (3 -6 month follow up only)  
 
 
 
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
12 
 14  
TABLE OF CONTENTS  
SCHEMA  ................................ ................................ ................................ ................................ ................................ ......................  11 
1 STUDY OBJECTIVES  ................................ ................................ ................................ ................................ .....................  14 
1.1 PRIMARY OBJECTIVES  ................................ ................................ ................................ ................................ ................................ ...... 14 
1.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ ................................ ................................ . 14 
1.3 CORRELATIVE STUDY OBJECTIVES  ................................ ................................ ................................ ................................ .................  14 
2 BACKGROUND  ................................ ................................ ................................ ................................ ...............................  15 
2.1 RADIATION TO THE PROSTATE : RATIONALE FOR TREATING PATIENTS WITH METASTATIC PROSTATE CANCER  ..............  15 
2.2 PROSTATE CANCER RADIOTHERAPY : RATIONALE FOR EXTREME HYPOFRACTIONATION SBRT  ................................ .........  [ADDRESS_512639]  ................................ ................................ ................................ ..............  18 
2.6 NEED FOR IGRT  IN PROSTATE RADIOT HERAPY  ................................ ................................ ................................ ...........................  18 
2.7 VIEWRAY: A UNIQUE RADIATION DELIVERY APPROACH  ................................ ................................ ................................ .............  19 
2.8 RATIONALE FOR CORRELATIVE STUDIES BACKGROUND : MICROBIOME AND BLOOD SAMPLE COLLECTION  ..........................  [ADDRESS_512640] SELECTION  ................................ ................................ ................................ ................................ ...................  20 
3.1 STUDY POPU LATION  ................................ ................................ ................................ ................................ ................................ .........  20 
3.2 INCLUSION CRITERIA  ................................ ................................ ................................ ................................ ................................ ........ 20 
3.3 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ................................ ....... 21 
4 REGISTRA TION PROCEDURES  ................................ ................................ ................................ ................................ . 21 
4.1 PATIENT REGISTRATION  ................................ ................................ ................................ ................................ ................................ .. 21 
5 STUDY PROCEDURES  ................................ ................................ ................................ ................................ ..................  22 
5.1 PRE-STUDY VISIT ................................ ................................ ................................ ................................ ................................ ..............  22 
5.2 IMAGING STUDIES  ................................ ................................ ................................ ................................ ................................ .............  22 
5.3 RADIATION TREATMENT PLANNING  ................................ ................................ ................................ ................................ .............  22 
5.3.1  Contours  ................................ ................................ ................................ ................................ ................................ ...............  22 
5.3.2  Dose/Treatment Planning Parameters  ................................ ................................ ................................ ....................  23 
5.4 SUPPORTIVE CARE GUIDELINES  ................................ ................................ ................................ ................................ .....................  23 
5.5 DURATION OF THERAPY AND CRITERIA FOR REMOVAL FROM STUDY  ................................ ................................ .....................  24 
5.6 DURATION OF FOLLOW UP ................................ ................................ ................................ ................................ ..............................  24 
6 DOSE MODIFICATIONS  ................................ ................................ ................................ ................................ ...............  24 
7 ADVE RSE EVENT REPORTING REQUIREMENTS  ................................ ................................ ................................  24 
7.1 ADVERSE EVENT DEFINITION  ................................ ................................ ................................ ................................ .........................  24 
7.2 RECORDING OF ADVERSE EVENTS  ................................ ................................ ................................ ................................ ..................  25 
7.2.1  Reporting of AE to WCMC IRB ................................ ................................ ................................ ................................ ..... 25 
7.3 DEFINITION OF SAE  ................................ ................................ ................................ ................................ ................................ .........  25 
7.3.1  Reporting of SAE to IRB  ................................ ................................ ................................ ................................ ..................  25 
7.4 EXPEDITED ADVERSE EVENT REPORTING  ................................ ................................ ................................ ................................ .... 25 
7.4.1  AE/SAE Follow Up  ................................ ................................ ................................ ................................ ............................  26 
8 PHARMACEUTICA L INFORMATION  ................................ ................................ ................................ .......................  26 
9 CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ................................ ..........................  [ADDRESS_512641]  ................................ ................................ ................................ ................................ ...... 27 
11 DATA REPORTING / REGULATORY CONSIDERATIONS  ................................ ................................ ..................  28 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
13 
 11.1  DATA COLLECTION  ................................ ................................ ................................ ................................ ................................ ...... 28 
11.2  REDC AP ................................ ................................ ................................ ................................ ................................ .......................  28 
11.3  REGULATORY CONSID ERATIONS  ................................ ................................ ................................ ................................ ...............  28 
11.4  DATA MANAGEMENT  ................................ ................................ ................................ ................................ ................................ .. 28 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ............................  29 
12.1  STUDY DESIGN /ENDPOINTS  ................................ ................................ ................................ ................................ .....................  29 
12.1.1  Primary Objectives  ................................ ................................ ................................ ................................ .....................  29 
12.1.2  Secondary Objectives  ................................ ................................ ................................ ................................ .................  29 
12.1.3  Correlative Study Objectives  ................................ ................................ ................................ ................................ ... 29 
12.2  SAMPLE SIZE/ACCRUAL RATE ................................ ................................ ................................ ................................ ..................  29 
12.3  ANALYSIS OF PRIMARY AND SECONDARY ENDPOINTS  ................................ ................................ ................................ ..........  29 
13 DATA AND SAFETY MONITORING PLAN (DSMP)  ................................ ................................ ..............................  31 
13.1  MONITORING PLAN  ................................ ................................ ................................ ................................ ................................ ..... 31 
13.2  STOPPI[INVESTIGATOR_16442]  ................................ ................................ ................................ ................................ ................................ .........  31 
14 REFERENCES  ................................ ................................ ................................ ................................ ................................ .. 31 
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
14 
  
1 STUDY OBJECTIVES  
 
HYPOTHESIS  1: Patients with metastatic  prostate cancer can un dergo MRI -guided prostate 
SBRT w/SIB without significant adverse events , similar to what has been reported for patients 
with localized prostate cancer  using CTCAE criteria . 
 
HYPOTHESIS 2: Patients with metastatic  prostate cancer who undergo MRI -guided pros tate 
SBRT will report good overall quality of life , similar to what has been reported for patients with 
localized prostate cancer. This will be measured using EPIC -26, I-PSS questionnaires, which are 
validated instruments that have been used to report QOL outcomes after prostate RT . 
 
HYPOTHESIS 3: Patients may experience decline in neutrophil:lymphocyte ratios during 
radiation therapy, that is most prominent at end of treatment, but recovers to baseline by [CONTACT_406571]. There will be alterations in the composi tion, diversity and abundance of microflora during 
radiation therapy  when the microbiome is compared at baseline, to post -treatment, to follow up . 
 
1.1 Primary Objectives   
  
1.11 To assess safety of  delivering MRI -guided prostate SBRT  in patients with metasta tic 
prostate cancer . 
 
   Treatment will be deemed safe of there is is no more than 3  acute >G3 likely radiation treatment 
related GI/GU toxicity within 3-6 months  after treatment (CTCAE 5.0 criteria)  completion .  
Given that the treatment plans will meet ri gorous normal tissue constraints used for standard 
prostate SBRT that have been established now with up to 10 year follow up data in patients with 
localized prostate ca ncer, we do not anticipate any increased toxicity on this study for metastatic 
prostate cancer patients.  
 
 
1.2 Secondary Objectives   
 
1.21 We will measure  quality of life (HRQOL) using : 1) the Expanded Prostate Cancer Index 
Composite (EPIC -26) short form ques tionnaire, 2) I-PSS. QOL assessments will occur  at 
baseline, [ADDRESS_512642] complete blood count (CBC) measurements at baseline, post -treatment and 3-[ADDRESS_512643] of SBRT on i mmune correlates and neutrophil lymphocyte ratios.  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
15 
 To describe gut microbiome changes (abundance, composition, diversity) associated with 
prostate radiation . 
  
 
2  BACKGROUND  
 
2.1 Radiation to the prostate: Rationale for treating patients with metastatic  prosta te cancer  
 
Next to  skin cancer, prostate cancer is the most commonly diagnosed cancer in men, and second 
leading cause of cancer death.[ADDRESS_512644], local therapy to the prostate (radical prostatectomy, definitive 
external beam radiation (EBRT)) was offered only to patients with non -metasta tic prostate 
cancer, and systemic therapi[INVESTIGATOR_406563] (ADT) was administered to 
patients with disease outside of the prostate. However, new data suggests that treatment of the 
primary tumor provides clinical benefit to men with m etastatic disease. 5,6  
 
The STAMPEDE  (Radiotherapy to the Primary Tumour  for Newly Diagnosed, Metastatic 
Prostate Cancer)  trial results demonstrate that  select  men with metastatic  prostate cancer derive 
an overall survival benefit from prostate -directed EBRT. In this randomized controlled phas e [ADDRESS_512645] of care plus prostate EBRT. The primary outcome was overall survival. With 
median follow up of 37 months, it was reported that patients wi th metastatic  prostate cancer had 
improved overall survival after prostate EBRT versus none, 3 year OS 81% vs 73% (HR 0.68, 
95% CI 0.52 -0.90, P=0.007). Based on these results, prostate EBRT has become a  standard 
treatment option for patients with  low meta static  burden  prostate cancer.5 Low metastatic burden 
prostate cancer is defined using the CHAARTED (Chemohormonal Therapy in Metastatic 
Hormone Sensitive Prostate Cancer) and STAMPEDE trial criteria: any meta static prostate 
cancer that does not have a) visceral metastases AND/OR b) four or more bone metastases with 
one or more outside the vertebral bodies or pelvis. Any patients without a) or b) are considered to 
have low metastatic burden .5,7 Furthermore, there is retrospective data suggesting that prostate 
RT improves outcomes in men with metastatic prostate cancer w ho do not necessarily fit the 
definition of low metastatic burden.32-33 
 
In the STAMPEDE study, patients rec eiving EBRT were allowed either 20 fractions of radiation 
to 55 Gy over 4 weeks, or 6 fractions of radiation to 36 Gy over 6 weeks. Neither of these  
regimens are commonly utilized in the [LOCATION_002]. Stereotactic body radiation therapy delivers 
36.25 Gy over 5 fractions in 1 -2 weeks, completing treatment in a short span of time with a low 
overall adverse event rate demonstrated in patients with non -metastatic prostate cancer1-3. In this 
study, we hope to demonstra te the safety and feasibility of delivering SBRT in patients with 
metastatic  prostate cancer , using MR -guided treatment delivery.  
 
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
16 
  
2.2 Prostate cancer radiotherapy : Rationale for extreme hypofractionation SBRT   
 
In the past, s tandard fractionation EBRT wa s delivered over [ADDRESS_512646] in deliverin g 
more radiati on dose per session,  to reduce the duration  of treatment. Compared to conventional 
fractionation, hypofractionation (higher dose of radiation given in fewer sessions) allows for 
reduced number of treatment visits, increasing patient convenien ce while lowering he alth care 
costs.  This has resulted in the development of extremely hypofractionated regimens, delivered 
most commonly within [ADDRESS_512647] 
commonly referred to as prostate stereotactic body radiation therapy ( SBRT).  
 
Single institutional and pooled reports have demonstrated similar efficacy and toxicity to 
conventionally fractionated regimens . 1-3  The NCCN treatment paradigm  currently includes 
SBRT as an alternative to conventionally fractionated regimens at centers with appropriate 
technology, physics and clinical expertise.8 SBRT  enables  patients to undergo a non -invasive 
treatment and be finished  in five treatments , achieving outcomes equivalent to  long-course 
EBRT or surgery, without a surgical procedure, general anesthesia  and the risk of associated 
complicati ons. As such, it is an excellent option to deliver prostate EBRT in patients with 
metastatic prostate cancer.  
 
 
2.3 Biological rationale for SBRT  
 
Proponents of prostate cancer hypofractionation argue that the rectum and bladder are less 
sensitive to increases  in dose per fraction t han prostate cancer and that therefore 
hypofractionation should yield negligible increases in late toxicity while providing improved 
cancer control. The / is a theoretical measure of a tissue’s predicted response to a dose of 
radia tion, relative to the s ize of the dose delivered per fraction. Conventional daily doses of 
radiation are based on the presumed high / ratios of most malignant tumors. Higher / ratios 
mean that tumor response is less dependent on the amount of radiation  administered with each  
fraction  when compared to adjacent normal tissue , and therefore that a lower radiation dose per 
treatment can typi[INVESTIGATOR_184411]. Lower tumor / ratios mean that a larger dose of radiation per 
treatment can provide improved efficacy  in terms of therapeuti c ratio, tumor control  versus risk 
of complications . A large body of work theorizes that the / for prostate cancer is low  (~1.5) , 
implying that a hypofractionated schedule could improve prostate cancer control , while 
maintaining a low risk of severe norm al tissue  complications  (see Table 1) . [ADDRESS_512648] 2 Gy fractions delivered five 
times a week.10-12   
 
 
Table 1. Equivalent total doses  in 2 Gy per fraction (EQD2)  based on / Biologically 
Effective Doses (BED)  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
17 
 
 /  (Gy) EQD2 
Standard (1.8 
Gy x 45 fx)EQD2 SBRT 
(7 Gy x 5 fx)EQD2 SBRT 
(7.5 Gy x 5 fx)EQD2 SBRT 
(8 Gy x 5 fx)EQD2 SBRT 
(8.5 Gy x 5 fx)EQD2 SBRT 
(9 Gy x 5 fx)
Total Dose (Gy) 81 35 37.5 40 42.5 45
Tumor 1.5 76.37 Gy 85 Gy 97.65 Gy 110 Gy 123.07 Gy 135 Gy
Fibrosis/stricture 2 76.95 Gy 78.75 Gy 89.06 Gy 100 Gy 111.56 Gy 123.7 Gy
Telangiectasia 4 78.3 Gy 64.17 Gy 71.88 Gy 80 Gy 88.54 Gy 97.5 Gy
Rectum 4 78.3 Gy 64.17 Gy 71.88 Gy 80 Gy 88.54 Gy 97.5 Gy
Bladder 4 78.3 Gy 64.17 Gy 71.88 Gy 80 Gy 88.54 Gy 97.5 Gy 
 
 
2.4 SBRT Outcomes   
 
To date, results from prospective and retrospective studies demonstrate good biochemical control 
and low toxicity for SBRT, with common ly used doses ranging from 35 -45 Gy in 5 fractions (see 
Table  2). Randomized data from the phase III PACE trial, compari ng standard fractionation 
EBRT to [ADDRESS_512649] fractionation EBRT  to 81 Gy , which has 10 -
year biochemical RFS of 91%, 78% and 62%, respectively, for low -, intermediate - and high -risk 
prostate cancer, and late Grade  3 gastrointestinal (GI) and genitourinary toxici ty of 1% and 5%, 
respectively.14 There is a lack of consensus regarding the appropriate dose to use for pr ostate 
SBRT. Extrapolating from dose escalation studies in conventionally fractionated EBRT,15,16 a 
higher dose  in SBRT  is hypothesized to result in improved local control.  However, delivery of 
higher dose results in s mall but significant increase in GU toxicity . Katz and Kang showed 
significantly higher late grade 2 -3 GU toxicity with 36.25 Gy compared to 35 Gy (13.2 vs 8.8%, 
P<0.05). With  35 Gy in five fractions, the m ajority of toxicity was grade 2, and overall toxicity 
was low without impacting GU quality of  life. As shown in Table 2, late grade 3 GU/GI toxicity 
after SBRT appears to be comparable to  that of  conventionally fractionated EBRT, ranging from 
0.6 – 3% 1,[ADDRESS_512650] median follow -up of 7 years.  
 
 
Table 2. Biochechemical c ontrol after prostate SBRT. *prospective  
Study  SBRT Dose 
(5 fx)  FU  # Pts  Risk Categories  bPFS  Toxicity ≥3  
Bolzicco
17* 35 Gy  36m  71 Low (41%), Int 
(42%), High (17%)  3y 94.4%  GI 0%, GU 
1% 
King18* 35-36.25 Gy  5y  41 Low, Favorable Int 
Risk 5y 92.7%  GI 0%, GU 
3.5%  
McBride
19* 36.25 -37.5 
Gy 44.5
m  45 Low 3y 97.7%  GI 4.4%, GU 
2.2%  
Madsen2
0* 33.5 Gy  41m  40 Low 4y 90%  GI 0%, GU 
0% 
Fuller21
* 38 Gy/ 4 fx  60m  259 Low (43%), Int  
(57%)  5y Low 
100%,  
 Int 88.5%  GI 0%, GU 
3.1%  
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
18 
 Kim22 45-50 Gy  42m  47 Low (38%), Int (62%)  4y 98%  GI 0%, GU 
0% 
Loblaw2
3* 35 Gy  55m  84 Low 5y 98%  GI 1%, GU 
1% 
Mantz24
* 40 Gy  60m 102 Low, Fav Int  5y 100%  GI 0%, GU 
0% 
Chen25 35-36.5 Gy  2.3y 100 Low (37%), Int 
(55%), High (8% ) 2y 99%  GI 0%, GU 
1% 
Katz 
and 
Kang2 35-36.25 Gy  72m  477 Low (68%) , Int (32%)  7y Low 
95.6%,  
Fav Int 
93.5%,  
Unfav Int 
79.3%  GI 0%, GU 
2% 
Katz 
and 
Kang26 35-36.25 Gy  84m  515 Low (63%), Int 
(30%), High (7%)  8y Low 
93.6%,  
Int 84.3%,  
High 65.0%  GI 0%, GU 
2% 
Katz27 35-36.25 Gy  108m  230 Low 10y 93%  GI 0%, GU 
2% 
Abbreviations: FU, follow up; Gy, Gray; Fx, fractions; m, months; y, years; IQR, interquartile 
range  
*SBRT monotherapy patients  
** Heterogeneous SBRT planning such that at least 1% of PTV receives ≥ 150% of prescription 
dose. 
 
2.[ADDRESS_512651]  
 
Both EBRT and SBRT target the entire prostate gland with radiation. Studies on patterns of 
failure following co nventional EBRT demonstrate that 85 -100% of local failures occur in the 
region of macroscopic tumor.28,[ADDRESS_512652] the ability to 
selectively target visible lesions within  the prostate  to a higher dose , resulting in heterogeneous 
dose distribution s that target high -risk nodules to increased dose and surrounding prostate to a 
lower dose.  A phase II trial  is currently ongoing  in the Netherlands  (Hypofractionated focal 
lesion ablative micr oboost in prostate cancer, “hypo -FLAME” [STUDY_ID_REMOVED]), to look at 
feasibility of a focal ablative boost with SBRT, using dose of [ADDRESS_512653] to 
visible nodules up to 50 Gy.  Furthermore, our department has a currently ongoi ng investigat or 
initiated protocol in patients with non -metastatic prostate cancer (“ MRI -guided Stereotactic 
Body Radioth erapy (SBRT) with Simultaneous Integrated Boost for Prostate Cancer ” PI: 
[INVESTIGATOR_207448], Silvia Formenti IRB Protocol #  [PHONE_4465] ), which utilizes  a simultaneous 
integrated boost in patients with non -metastatic prostate cancer, and has demonstrated the 
feasibility and safety of such an approach in [ADDRESS_512654] in this protocol , 40 Gy, remains within the acceptable range of 
doses for prostate SBRT.  
 
2.6 Need for IGRT in prostate r adiotherapy  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
19 
 SBRT delivers high dose to the target with a rapid dose fall -off. Thus, it is important to account 
for prostate motion as much as possible du ring treatment delivery  (intrafraction motion), and 
between each treatment fraction (interfraction motion) . A small shift in the prostate , if 
unaccounted for,  can result in significantly decreased dose to the target . Position changes are  
inevitable due to bowel gas/stool fluctuation, bladder filling and/or prostate edema from 
radiation .30 There are multiple techniques to account for prostate motion during delivery of 
SBRT. Such techniques include tracking via implan ted radiofrequency transponders (e.g., 
Calypso), on -board kV imaging of prostate fiducials at 30 -60 second intervals (e.g., Cyberknife), 
and use of multiple cone -beam CTs during treatment. Traditional image -guided radiation is 
unable to provide real -time f eedback of target position. Treating multiple radiation targets 
(prostate, seminal vesicles, high -risk nodules) with steep dose gradients becomes particularly 
challenging with standard image guidance systems,  because adjustments are made offline  or at 
prolonged select intervals during treatment delivery.  
 
 
2.7 ViewRay: a unique radiation delivery approach  
 
The ViewRay MRIdian Linac system is a radiation delivery machine that integrates a linear 
accelerator with r eal-time MRI imaging. The ViewRay machine allows  fusion of MR imaging 
with treatment planning. The uniqueness of this approach is the image guided delivery  
component,  based on  precise MRI -based detection of target and normal tissue during treatment 
in rea l-time. The ViewRay will provide real -time MRI i maging to ensure that the high -dose 
region is precisely targeted.  MRI guided radiation has the benefit of not requiring fiducial 
implantation or excess radiation exposure from multiple cone beam CT. Furthermo re, motion 
monitoring can be performed with imag es acquired up to 4 frames a second, allowing live 
feedback of treatment position.  
 
ViewRay offers  the ideal system for delivery of prostate SBRT, due to its ability to provide 
image guidance “live”, during treatment. Real -time MRI imaging allows superior  soft-tissue 
differentiation with excellent visualization of the prostate. This ViewRay platform offers the 
ideal setting for this study, that aims at precisely  deliver ing prostate SBRT with a simultaneous 
integrated boost to visible nodules. MRI guided ra diation, a property unique to ViewRay, will  be 
exploited in the current trial to deliver precise treatm ent with resultant lower dose to surrounding 
normal structures.  
 
The goal of this study is to assess safety of treating patients with metastatic  prostat e cancer with 
MRI -guided prostate SBRT.  Safety is defined  as lack of  more than 3  patients with treatment 
related acute >G3 GI or GU toxicity  within 3- [ADDRESS_512655] treatment . The proposed SBRT 
dose (36.25  Gy in 5 fractions  to the whole prostate ) has been  reported in the literature to be safe 
and well tolerated (Table 2), with no acute G3 toxicity. The proposed boost dose  to [ADDRESS_512656] of care SBRT doses, and is also 
expected to be well -tolerated.  Furthermore, it has been tested in our currently ongoing 
investigator initiated protocol  in patients with non -metastatic prostate cancer  (“MRI -guided 
Stereotactic Body Radioth erapy (SBRT) with Simultaneous Integrated Boost for Prostate 
Cancer ” PI: [INVESTIGATOR_406564], Silvia Formenti IRB Protocol #  [PHONE_4465] ). As of 4/29/19, [ADDRESS_512657] ate 
cancer , though it is possible that the addition of systemic therapy may alter likelihood of toxicity . 
  
2.8 Rationale for Correlative Studies Background : Microbiome  and blood sample collection  
Patients accrued to the study will  donate  a stool specimen and a blood sample both before and 
after radiation, to study their changes in the microbiome and circulating immune correlates 
during and after radiotherapy , and at 3-6 month  follow up . 
  
Preliminary results from our ongoing study “Effect  of Radiotherapy Variables on Circulating 
Effectors of Immnue Response and Local Microbiome” PI: [INVESTIGATOR_406565],  IRB Protocol #:  
[PHONE_8390]  demonstrate depletion of circul ating lymphocytes in prostate cancer patients 
undergoing protracted standard radia tion compared to 5 -fraction SBRT (which is the regimen we 
will use on this study)  (results submitted to ASTRO) . We will study this phenomenon further in 
patients undergoing S BRT on this study. We have also found a temporary increase in 
neutrophil:lymphocyt e ratio  (NLR)  during radiation to the prostate  in our dataset of patients; 
patients enrolled on this protocol will also have assessment of NLR at baseline, after RT and at 
3-month follow up . 
 
The host microbiome is an emerging topic of investigation, with growing evidence that 
commensal microbiota impacts anti -tumor immune response, and sensitivity to systemic 
therapi[INVESTIGATOR_70050].   Commensal bacteria outnumber human ce lls by [CONTACT_2669] [ADDRESS_512658] the immune system thr ough a number of mechanisms, including 
possible modulation of myeloid -derived cells; stimulation of T helper cells, and enhancement of 
memory T -cell response. Dysbiosis, or shifts in microbial composition, may modulate response 
to cancer therapy. We hypoth esize that the underlying microbial community composition will be 
impacted by [CONTACT_406572]. Our preliminary data in mice suggests 
fluctuations in composition, abundance and diversity after local tumor -directed radiation. We 
hope to explore this further in patients who are undergoing SBR T by [CONTACT_406573], upon completion of RT, and at follow up.  
 
 
[ADDRESS_512659]  SELECTION  
 
3.1 Study Population  
 
Men with a histologically confirmed diagnosis of metastatic prosta te adenocarcinoma, meeting 
the inclusion and exclusion criteri a below, and electing to undergo definitive radiation treatment  
with SBRT , will be eligible for participation in this study.  
 
3.2 Inclusion Criteria  
 
1. Biopsy -proven diagnosis of prostate adenoca rcinoma  
2. Age ≥ [ADDRESS_512660] metastatic prostate cancer proven on biopsy or imaging   
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
21 
 3.3 Exclusion Criteria  
 
1. History of prior pelvic radiation (external beam or brachytherapy ) 
2. Inability to undergo MRI  
3. AUA score >[ADDRESS_512661] be within six months of start of therapy  
unless exception is made by [CONTACT_406574] (Drs. Kang, Formenti or Sternberg)  
  
 
4 REGISTRATION PROCEDURES  
  
4.1   Patient Registration  
 
 
Before any protocol specific procedures can be carried out, investigators/s taff will 
fully explain the details of the protocol, the study procedures and the aspects of patient 
privacy regarding research information. Patients will be provided a comprehensiv e 
explanation of the proposed treatment including the type of therapy, the rationale for 
treatment on the protocol, alternative treatments that are available, any known adverse 
events, the investigational nature of the study and the potential risks and ben efits of the 
treatment. The informed consent document will meet all require ments of the Institutional 
Review Board (IRB). All subjects/patients are informed in the consent that participation or 
refusal to participate in the research study will not affect a ny of the clinical treatment or 
services to which they would otherwise be e ntitled.  
The physicians who may obtain informed consent are listed on the title page of 
this protocol. The informed consent form will be signed by [CONTACT_406575] g physician. Once signed, a copy will be given to the patient and one will be 
maintained with the patient’s medical record. Once eligibility is confirmed and informed 
consent is documented, the patient will be registered by [CONTACT_9137]/data 
manag er. 
Patients will be centrally registered with the Office of Billing Compli ance. To register a 
patient, submit the following documents via the JIRA Registration Process:  
 
• Legible copy of the HRBAF  
• Signed informed consent  
 
 Registration must be completed within 24 hours of the signing of informed consent.  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
22 
  
 
5 STUDY PROCEDURES  
 
              
Pre-Study  Fx 1 Fx2 Fx 
3 Fx 
4 Fx 5* Post-RT Visit s 
(3-6  month s, 9-
12 months  s/p 
RT) 
Informed consent  X        
 
Demographics   
X  
  
  
  
  
  
  
PSA  
X  
   
   
   
   
   
 X 
 
Acute/Late Toxicity 
Assessment 
(CTCAE)   
X  
  
  
  
  
X  
X 
 
EPIC -26, I-PSS  
X  
   
   
   
   
   
X 
Imaging: Planning 
CT/MR;   
       X       
Blood draw and 
microbiome sample        X      X X** 
    
** no blood draw at 9 -12 months.  
 
5.1 Pre-Study Visit  
 
At the initial screening visit, patient will undergo:  
o Informed consent  
o Medical hi story  
o Baseline EPIC -[ADDRESS_512662] simulation to allow for a comfo rtably full bladder, if tolerated ; this will be 
modified  according to physicians discretion .  A radiation planning MR will be obtained at the 
physician’s discretion.  
 
 
5.3 Radiation Treatment Planning  
 
5.3.1 Contours  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
23 
 The prostate +/ - seminal vesicles (SV) will be contoured as the clinical target volume (CTV)  as 
per usual practice . For patients with identifiable dominant intraprostatic nodules 
(Select  PI[INVESTIGATOR_207451] 3-5 and/or PSMA avid (if PSMA PET/MR is available)  and/ or biopsy 
positive  nodules (chosen based on physician's clinical judgment  and correlation with biop sy 
findings) ), there is the option for  DIN to be contoured as gross tumor volume(s) (GTV).  There 
will be no planning target volume (PTV) expansion for the  DIN GTV. The PTV expansion for 
the CTV will be 0-[ADDRESS_512663] care . 
 
The rectum will be drawn from the bottom of the ischial tuberosities to the sigmoid flexure. The 
urethra will be delineated on MRI  from the prostatic apex, to entry of urethra into the penile 
bulb, using a 5-6 mm brush .   
 
The bladder, femoral heads, penile bulb will also be contoured as normal structures.  
 
5.3.2 Dose /Treatment Planning Parameters  
 
The CTV (prostate +/ - SV) will be treated  to dose of 36.25 Gy in 5 fractions. For patients with 
identifiable DINs, at the physician’s discretion, there is an option for  a simultaneous integrated 
boost to PI[INVESTIGATOR_207451] 3-5 or PSMA avid  nodules  and/or biopsy positive nodules , delivering 40 Gy  to 
the conto ured nodule (s) as a mean dose while respecting normal tissue constraints to rectum and 
urethra. (If normal tissue constraints to the rectum and urethra can not be achieved, the DIN will 
be boosted to a lower dose, or not boosted ) 
 
Volume of the PTV receivi ng prescribed SBRT dose  should  ideally  be ≥ 95% ; acceptable 
suggested deviation is dose > 85% 
 
Critical organ limits  (SBRT monotherapy) : 
1. Rectum: Maximum dose  to 1 cc  38.5 Gy , Max dose to 3 cc 34.4 Gy,,  Max point dose 40 
Gy. Acceptable deviation is maximum dose to 1  cc 39 Gy, max dose to 3 cc 36 Gy and max 
point dose of 42 Gy.  
 2. Bladder: Maximum dose  to 1 cc 38.5 Gy, Max point dose 40 Gy . Acceptabl e deviation is 
max point dose of 42 Gy . 
3. Penile Bulb:  No more than 1 05% of prescription dose; D3cc 2 5 Gy. This is a soft 
constraint.  
 4. Femoral hea ds: Maximum point dose 30 Gy  
 5. Small bowel: Maximum point dose 25 Gy    
6. Urethra: Max dose 40 Gy. Will allow up to 42 Gy  point dose . Urethra planning organ at 
risk volume (PRV) can be created around the contoured urethra if there is uncertainty  
 
 
5.4 Suppor tive Care Guidelines  
 
a. Urinary:  A proportion of patients undergoing prostate S BRT  can expect increase in 
urinary frequency or urgency. I f this becomes bothersome to the patient, medication to 
alleviate symptoms can be prescribed at the discretion of the tre ating radiation oncologist 
and documented in patient chart.  
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
24 
 b. Bowel : Bowel symptoms during time of prostate SBRT can occur . If patients d evelop 
rectal urgency, tenesmus or diarrhea, medication to alleviate symptoms can be prescribed 
at the discretion of the treating radiation oncologist, and documented in patient chart.  
    
5.5 Duration of Th erapy and Criteria for Removal f rom Study  
 
In the absence of treat ment delays , the SBRT is anticipated to complete within 2 -3 weeks time. 
Patients will undergo radiation 2 -3 times a week, but treatment can be slowed down to once a 
week at the physician’s di scretion; these differing fractionation patterns fall within standard of 
care for SBRT . Patients can be removed from the study at any point should they decide they no 
longer  wish to participate. They will continue to receive routine medical care as necessary 
outside the confines of this study.  
 
Patients will be placed in a prospective database patients undergoing prostate SBRT in our 
department. As per our usu al care, they wi ll fill out I-PSS and EPIC -[ADDRESS_512664] care. For purposes of this study, patients will be 
followed with CTCAE evaluation, EPIC -26 quality of life questi onnaire, I-PSS scores at each 
follow up visit (3 -6 months; 9 -12 months) ; afterwards they will be pros pectively followed as per 
usual care in the Radiation Oncology  department  with quality of life questionnaires and adverse 
event evaluation, I-PSS scores.  
 
6 DOS E MODIFICATIONS  
 
None.  
 
7 ADVERSE EVENT REPORTING REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
investigator will be required to provide appropriate information concerning any findings that 
sugg est significant hazards, contraindications, side effects, or preca utions pertinent to the safe 
use of the drug or device under investigation.  Safety will be monitored by [CONTACT_406576], as well as by [CONTACT_406577] l aboratory tests, x -rays, electrocardiographs, etc.  
 
7.1 Adverse Event Definition  
 
An adverse event (also referred to as an adverse experience) can be any unfavorable and 
unintended sign (e.g., a n abnormal laboratory finding), symptom, or disease tempo rally 
associated with  treatment , and does not imply any judgment about causality.   
 
 Adverse Event Characteristics and Related Attributions  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
25 
  CTCAE term (AE description) and grade:  The descriptions  and grading scales found in 
the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be 
utilized for grade 3 or higher AE reporting.  A copy of the CTCAE version 4.0 can be 
downloaded from the CTEP web site ( http://ctep.cancer.gov ). 
 
• Attribution  of the AE:  
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlike ly – The AE is doubtfully related to the study treatment.  
- Unrelated – The AE is clearly NOT related  to the study treatment.  
   
7.2 Recording of Adverse Events  
 
All adverse events will be recorded on a patient specific AE log. The AE log will be maintained 
by [CONTACT_170070]’s research chart.     
 
7.2.1 Reporting of AE to WCMC IRB  
 
All AEs occurring on this study will be reported to the IRB according to 
the IRB policy, which can be accessed via the following link:  
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immed
iate_Reporting_Policy.pdf .  
 
7.3 Definition of SAE  
 
SAE’s include death, life threatening adverse experiences, hospi[INVESTIGATOR_207456], disability or incapacitation, overdose, congenital anomalies and any 
other serious events that may jeopardize the subject or require medical or surgica l 
intervention to prevent one of the out comes listed in this definition.  
 
7.3.1 Reporting of SAE to IRB  
 
All SAEs occurring on this study will be reported to the IRB according to the IRB policy, which 
can be accessed via the following link:  
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting_Policy
.pdf.  
 
7.4 Expedited Adverse Event Reporting  
  
The principal investiga tor is responsible for monitoring the sa fety of patients who enroll in 
the study.  All AEs occurring after treatment  will be followed until resolution.  The 
descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be used for 
adverse event reporting.  A copy of the CTCAE v ersion 4.0 can be downloaded from the 
CTEP web site (http://ctep.cancer.gov/reporting/ctc.html ). 
A serious adverse event (SAE) is any adverse experience that results in any of the following 
outcomes : 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
26 
 - Death.  
- Life-threatening adverse experience.  
- Requires inpatient hospi[INVESTIGATOR_1081].  
- Persistent or significant disability/incapacity.  
- A congenital anomaly/birth defect.  
• Important medical events: Defined as AEs that,  based upon appropriate medical 
judgment, may jeopardize the patient and may require medical or surgical intervention to 
prevent 1 of the outcomes liste d above, even though these events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_11298].  
All SAEs occurring on this study will be reported to the IRB according to the IRB policy, 
which can be accessed via the following link:  
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting_Po
licy.pdf .  
 
7.4.1 AE/SAE Follow Up  
 
All SAEs and AEs reported d uring this study will be followed until resolution or until the 
investigator confirms that the AE/SAE ha s stabilized and no more follow -up is required. 
This requirement indicates that follow -up may be required for some events after the patient 
discontinue s participation from the study.  
 
 
8 PHARMACEUTICAL INFORMATION  
 
There is no investigative agent used on thi s protocol.  
 
9 CORRELATIVE/SPECIAL STUDIES  
 
 
9.1 Correlative Study: Blood draws for immune correlates and microbiome collection  
Patients will provide  blood draw prior to, at the completion of radiation  and at [ADDRESS_512665] 
treatment  follow up . They will a lso be providing a stool sample for microbiome analysis  at 
baseline, end of completion and 3-6 month follow up  (last stool sam ple is optional) . This is a 
correlative study.  
 
Blood Sample Collection and Procedure  
Blood  samples  (40-ml) will be collected  in heparinized  “Green  Top”  tubes  (for PBMC  
and plasma  isolation)  and processed  within  4 h of sample  receipt.  The PBMC  will be 
isolated  using  a 1.077  g/ml Ficoll  layer  to enrich  the leukocytes  and remove  the dead  cells 
and any red cells,  and cryopreserved  in 10% DMSO,  90% human  AB serum  at 10 x 106 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
27 
 cells/vial  and stored  in liquid  nitrogen  for batch  analysis.  Plasma  will also be aliquoted  and 
stored  at -800C for batch  analysis. We anticipate analyses of T cell subsets and 
neutrophil/lymphocyte ratios, as well as cytokine measurement and proliferation analyses (all 
markers of peripheral immune correla tes to assess status over time) . 
  
 
Microbiome collection  
Collection of Specimen(s): Patients will be provided with a stool collection container and be 
instructed on p roviding a specimen  appropriately , which can be done from home or in the clinic.  
 
Handling of Specimens(s):  Samples  received  will be promptly frozen at [ADDRESS_512666] es are collected.   
 
The microbial DNA will be isolated and used to provide DNA sequence information. We will 
perform taxonomic characterization of bacteria (using 16S rRNA). Prokaryotic diversity will be 
screened using massively parallel DNA sequencing, ex ploiting a multiplexing technique to 
generate 16S rRNA sequence tags, followed by [CONTACT_207471] (statistical, clustering, and 
phylogenetic) to estimate the distribution of phyloty pes, differential abundance, and the relative 
contributions between phylotypes and  community dissimilarities to the overall diversity in 
individuals.  
  
We will examine whether there are metagenome sequence content changes during radiation 
treatment, and s tudy whether differences in gene content indicate differences in functional 
pathwa ys between the normal and irradiated microbiome using pathway analysis.   
 
Samples will be collected by [CONTACT_207472] -80C freezer in 
[CONTACT_207484]’s lab until sample analysis.  
 
 
[ADDRESS_512667]  
 
This i s a safety study.  
 
Treatment will be deemed safe of there are no more than 3  acute  greater than  grade 3 radiation 
treatment related GI/GU adverse events  within  3-6 months  of treatment ( CTCAE 5.0  criteria).   
 
The primary endpoint will be safety, as measured by [CONTACT_406578]/GU toxicity within 3-[ADDRESS_512668] SBRT.  
 
 
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
28 
 11 DATA REPORTING / REGULATORY C ONSIDERATIONS  
 
11.1 Data Collecti on 
 
The data collection plan for this study is to utilize REDCap  to capt ure all treatment, 
toxicity, efficacy, and adverse event data  for all enrolled patients.   
 
11.2 REDCap  
 
REDCap (Research Electronic Data Capture) is a free data management software system that is 
fully supported by [CONTACT_57421] -Cornell Medical Center CTSC.  It is a tool for the creation of 
customized, secure data management systems that include Web -based data -entry forms, 
reporting tools, and a full array of security  features including user and group based privileges, 
authentication using institution LDAP system, with a full audit trail of data manipulation and 
export procedures.  REDCap is maintained on CTSC -owned servers that are backed up nightly 
and support encryp ted (SSL -based) connections.  Nationally, the software is developed, 
enhanced and supported through a multi -institutional consortium led by [CONTACT_406579].  
 
 
11.[ADDRESS_512669] data manager at JCTO. Once the discrep ancy is closed, by [CONTACT_112536] 
“resolved” or “irresolvable”, the data is marked clean and an audit trail is generated by [CONTACT_28049].  
All key end points will be source verified by a second p erson at each site and errors will be 
corrected. Once the data is verif ied and all discrepancies are closed, the data can be 
locked/frozen. Locking and freezing can be done at different granular levels and will follow 
institutional SOPs and any specific re quirements for the project.  
Security measures that will be taken in ord er to protect patient data will include firewall 
technology and database level security which will be achieved by [CONTACT_406580] [ADDRESS_512670] . Additional security for data transfer between remote clients and 
servers will be achieved by [CONTACT_166019]/SSL. All data will be backed -up to tape 
periodically according to the Institutional SOPs. All data will be stored for at least 5 years  
following the termination of this study.  
 
 
12 STATISTICAL CONSIDERATIONS  
 
12.1  Study Design/Endpoints  
 
12.1.1  Primary Objectives    
Safety of this approach will be determined by [CONTACT_207463]/GU toxicity (CTCAE 5).  The 
treatment will be deemed safe if no more than  3 patients ex perience a grade 4 likely radiation 
treatment related  GI/GU (or higher) adverse event within 3-6 months  from the end of  treatment.  
 
 
12.1.2  Secondary Objectives   
 
Secondary objectives include quality of life (HRQOL) measure s including: 1)  the Expand ed 
Prostate Cancer Index Composite (EPIC) short form questionnaire, 2) International Prostate 
Symptom Score (I -PSS).  These will be assessed at baseline , at the [ADDRESS_512671] microbiome and peripheral immune correlates fo und in blood.    
 
 
12.2 Sample Size/Accrual Rate  
 
We plan to accrue 2 0 patients over 2 years, or about 4 -6 patients every 6 months.   
 
12.3 Analysis of Primary and Secondary Endpoints  
 
Primary Endpoint:  
The treatment will be deemed safe if the grade 4+  likely radiati on treatment related  GI/GU 
adverse event rate is less than 10% within 3-6 mo nths of the end of treatment.   The proportion of 
patients that experience a >grade 3 GU/GU adverse event will be determined with a binomial 
Protocol [ADDRESS_512672] 95% binomial confidence  interval . If the lower bound of 
the interval is below 10%, the treatment will be considered safe.  
 
Secondary Endpoints : 
QOL  measures at baseline and at fol low up (3-[ADDRESS_512673] treatment start , and 9-12 months ) 
will be summarized numerically and graphic ally using mean (sd), median (interquartile range), 
or count (percent) as appropriate, and 95% confidence intervals estimated where possible. The 
QOL value will be plotted over time with a line for each patient and a smoothed curve s uper-
imposed on the plo t. Changes in scoring from pre - to post -treatment will also be determined . 
EPIC -26 overall scores as well as domain summary scores (urinary incontinence, urinary 
irritative/obstructive, bowel, sexual, hormonal) and individual item re sponses will be evaluat ed. 
Similarly, overall score as well as individual item responses will be assessed for the  I-PSS 
survey .  
Toxicity will be assessed using CTCAE 5.0 criteria at 3 -6 months and 9 -12 months.  
These analyse s will be descriptive.  
 
Correl ative study endpoints:  
Microbiome  
Statistical analysis of microbiome and metagenome composition will be performed in the R 
statistical programming environment  using package phyloseq , which incorporates and builds 
upon community ecology packages such as ade4 and vegan  and employs the flexible graphic 
system ggplot2, to easily visualize complex data relationships.  For 16S data, we will evaluate the 
adequacy of sequencing efforts using rarefaction plots. Alpha diversity index for each will be 
characterized thr ough dominan ce, equitability, richness, evenness. The diversity metrics will be 
calculated at OTU and higher taxonomical levels to best characterize the community structure. 
We will test for associations of each of these alpha diversity metrics with the ti me relative to 
radiation exposure, using one -way ANOVA after even -sampling the observations to a depth cut -
off maximizing the number of samples and depth. In addition, rank -abundance plots will be used 
to visualize differences in abundance of dominant taxa  in the clin ical and phenotypic groups. We 
will utilize skyline plots to visualize the patterns of community structure in terms of relative 
abundances in the collected samples between before and after the radiation treatment . Similarly, 
for metagenomic dat a, skyline p lots will be used to reveal functional compositions of the 
samples. Heat -maps will be plotted to visualize clustering patterns in the data.  
 
We will study the evolution of microbiome over time as a consequence of  the radiation 
treatment.  The r elative abundances at each taxonomical level will be first normalized by [CONTACT_26500] -
ratio transformation. Then the transformed relative abundance of each individual taxa at multiple 
time points will be fitted by [CONTACT_406581] a nd all subject -
specific characteristics as the independent covariates. For the nonlinear trend, we will combine 
the nature splines with linear mixed model in the data analysis.  The same model will be applied 
on the indices calculated in the ecology microb ial analysis.    
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
31 
 CBC collection  
Plasma s amples will be collected at three  time points: before radiation, following completion, 
and [ADDRESS_512674], 
NLR  will be numerically and graphically summarized in several ways. The average ratio at each 
time will be estimated,  as well as average changes from baseline, and individual trajectories will 
be plotte d in “spaghetti plots.”   Parallel summaries will be presented dichotomizing N/L ratio at 
4%, counting the proportion of patients above this threshold at each time point.  
  
Several markers beyond N/L ratio are of interest in order to thoroughly characteriz e changes 
throughout radiation treatment, including continuous (e.g. T cell panel and TREG panel, IL -7, 
IL-15, IL -6, IL -10, IL -17, IL -2 cytokines), and categorical (e.g. p roliferative ability) measures. 
These will be summarized and analyzed in an explorato ry manner in parallel methods to N/L 
ratio, if funding is secured for these analyses.  
  
13  Data and Safety Monitoring Plan (DSMP)  
 
The WCMC Data and Safety Monitoring Commit tee (DSMC) is the central monitoring board 
for this study.  
 
13.[ADDRESS_512675] patient is enrolled. Reports to the Data Safety an d 
Monitoring Committee will include the following information: accruals, targets, responses, 
adverse events and evidence of reporting to appropriate review committees. The WCMC 
Data and Safety Monitoring Board (DSMB) will review the IRB approved protocol, the data 
and safety monitoring plan and any stoppi[INVESTIGATOR_207458]. During the 
course of the study, the DSMB will review cumulative study data twic e a year to evaluate 
safety, efficacy, study conduct, and scientific validity and int egrity of the trial. The WCMC 
DSMB may also convene as needed if stoppi[INVESTIGATOR_406566]/or IRB would  like the WCMC DSMB to address.  
 
13.[ADDRESS_512676] possibly related to treatment. A decision will be made 
with approval of the DSMB to either modify the protocol or to terminate the trial due to an 
unacceptable adverse event rate.  
 
 
14 REFERENCES  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
32 
  
 
1. Katz A, Kang J. Stereotac tic body radiotherapy with or without external beam radiation 
as treatment for organ con fined high -risk prostate carcinoma: a six year study. Radiat 
Oncol. 2014;9:1.  
2. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low - and 
intermediate -risk prostate carcinoma, a 7 -year study. Front Oncol. 2014;4:240.  
3. King  CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized 
prostate cancer: pooled analysis from a multi -institutional consortium of prospective 
phase II trials. Radiother Oncol. Nov 2013;109(2):217 -221. 
4. Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2016. CA Cancer J Clin. Jan-Feb 
2016;66(1):7 -30. 
5. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly 
diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 
trial. Lancet. Dec 1 2018;392([ZIP_CODE]):[ADDRESS_512677] of definitive local therapy 
for lymph node -positive prostate cancer: a population -based study. International journal 
of radiation oncology, biology, physics. Apr 1 2014;88(5):1064 -1073.  
7. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in 
Metastatic Hormone -Sensitive Prostate Cancer: Long -Term Survival Analysis of the 
Randomized Phase III E3805 CHAARTED Trial. Journal of clinical oncology : offi cial 
journal of the American Society of Clinical Oncology. Apr 10 2018;36(11):1080 -1087.  
8. Network NCC. Prostate Cancer. 2016(01.2016).  
9. Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal 
radiotherapy dose to treat prostat e cancer? A meta -analysis of biologically equivalent 
dose escalati on. Radiother Oncol. Jun 2015;115(3):295 -300. 
10. Withers HR, Thames HD. Dose fractionation and volume effects in normal tissues and 
tumors. Am J Clin Oncol. Jun 1988;11(3):[ADDRESS_512678] curve for chang e in dose per 
fraction. Radiother Oncol. Nov 1983;1(2):187 -191. 
12. Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M. 
Hypofractionated radiotherapy for prostate cancer. Radiat Oncol. Dec 6 2014;9:275.  
13. Morrison K, Tree AC, Khoo V, Van As NJ. The PACE trial: International randomised 
study of laparoscopic prostatectomy vs. stereotactic body radiotherapy (SBRT) and 
standard radiotherapy vs. SBRT for early stage organ -confine d prostate cancer. Journal 
of Clinical Oncology. 2019;36(6S).  
14. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten -year outcomes of high -dose, intensity -
modulated radiotherapy for localized prostate cancer. Cancer. Apr 1 2011;117(7):[ADDRESS_512679], He emsbergen WD, Koper PC, et al. Dose -response in radiotherapy for 
localized prostate cancer: results of the Dutch multicenter randomized phase III trial 
comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. May 1 2006;24(13):1990 -
1996.  
16. Beckendorf V,  Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized pros tate 
cancer: 5 -year results of GETUG 06 randomized trial. International journal of radiation 
oncology, biology, physics. Jul 15 2011;80(4):[ADDRESS_512680] 17 2013;13:49.  
18. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC,  Jr. Stereotactic body 
radiotherapy for localized prostate cancer:  interim results of a prospective phase II 
clinical trial. International journal of radiation oncology, biology, physics. Mar 15 
2009;73(4):1043 -1048.  
19. McBride SM, Wong DS, Dombrowski JJ,  et al. Hypofractionated stereotactic body 
radiotherapy in low -risk prostate adenocarcinoma: preliminary results of a multi -
institutional phase 1 feasibility trial. Cancer. Aug 01 2012;118(15):3681 -3690.  
20. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L,  Corman J. Stereotactic 
hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five 
fractions for localized disease: first clinical trial results. International journal of radiation 
oncology, biology, physics. Mar 15 2007;67(4):1099 -1105. 
21. Fuller D, Kane BL, Medbery CA, et al. 5 -year outcomes from a prospective multi -
institutional trial of heterogeneous dosing stereotiactic body radiotherapy (SBRT) for 
low- and intermediate -risk prostate cancer. J Clin Oncol. 2017;35(suppl 6S):abstrac t 35. 
22. Kim DN, Straka C, Cho LC, et al. Early and multiple PSA bounces can occur following 
high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 
trial. Practical radiation oncology. Jan - Feb 2017;7(1):e43 -e49. 
23. Lobla w A, Cheung P, D'Alimonte L, et al. Prostate stereotactic ablative  body 
radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological 
outcomes. Radiotherapy and oncology : journal of the European Society for Therapeutic 
Radiolog y and Oncology. May 2013;107(2):153 -158. 
24. Mantz C. A Phase II T rial of Stereotactic Ablative Body Radiotherapy for Low -Risk 
Prostate Cancer Using a Non -Robotic Linear Accelerator and Real -Time Target 
Tracking: Report of Toxicity, Quality of Life, and Di sease Control Outcomes with 5 -
Year Minimum Follow -Up. Frontiers in  oncology. 2014;4:279.  
25. Chen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically 
localized prostate cancer: the Georgetown University experience. Radiat Onc ol. Mar 13 
2013;8:58.  
26. Katz A, Formenti SC, Kang J. Predicting Biochemical Disease -Free Survival after 
Prostate Stereotactic Body Radiotherapy: Risk -Stratification and Patterns of Failure. 
Frontiers in oncology. 2016;6:168.  
27. Katz A. Stereotactic Body Radiotherapy for Low -Risk Prostate Cancer: A Ten -Year 
Analysis. Cureus. 2017;9(9):e1668.  
28. Arrayeh E, Westphalen AC, Kurhanewicz J, et al. Does local recurrence of prostate 
cancer after radiation therapy occur at the site of pr imary tumor? Results of a longitudinal 
MRI and MRSI study. International journal of radiation oncology, biology, physics. Apr 
1 2012;82(5):e787 -793. 
29. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in 
patients treated wi th hormonal therapy and radiotherapy: implications f or conformal 
therapy planning. International journal of radiation oncology, biology, physics. Jul 1 
2002;53(3):595 -599. 
30. King BL, Butler WM, Merrick GS, et al. Electromagnetic transponders indicate pro state 
size increase followed by [CONTACT_207483]. 
Int J Radiat Oncol Biol Phys. Apr 1 2011;79(5):1350 -1357.  
 
Protocol 19 -04020263  
Version  5.0 2 6JUL2023  
34 
  